OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of “Hold” from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have been given an average recommendation of “Hold” by the five research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $6.3333.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a report on Tuesday, April 21st.

Institutional Trading of OKYO Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of OKYO. Renaissance Technologies LLC increased its holdings in shares of OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of OKYO Pharma in the fourth quarter valued at approximately $36,000. Finally, Citadel Advisors LLC acquired a new stake in shares of OKYO Pharma in the third quarter valued at approximately $31,000. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Price Performance

Shares of OKYO Pharma stock opened at $1.55 on Thursday. The firm has a 50 day simple moving average of $1.61 and a 200 day simple moving average of $1.81. OKYO Pharma has a fifty-two week low of $1.42 and a fifty-two week high of $3.35.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.